Carolyn M Rutter1, Amy B Knudsen2, Tracey L Marsh3, V Paul Doria-Rose4, Eric Johnson5, Chester Pabiniak5, Karen M Kuntz6, Marjolein van Ballegooijen7, Ann G Zauber8, Iris Lansdorp-Vogelaar7. 1. RAND Corporation, Santa Monica, CA, USA (CMR) 2. Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA (ABK) 3. Department of Biostatistics, University of Washington, Seattle, WA, USA (TLM) 4. National Cancer Institute, Health Systems & Intervention Research Branch, Bethesda, MD, USA (VPD) 5. Group Health Research Institute, Seattle, WA, USA (EJ, CP) 6. Department of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA (KMK) 7. Department of Public Health, Erasmus MC, Rotterdam, Netherlands (MVB, IL) 8. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA (AGZ)
Abstract
BACKGROUND: Microsimulation models synthesize evidence about disease processes and interventions, providing a method for predicting long-term benefits and harms of prevention, screening, and treatment strategies. Because models often require assumptions about unobservable processes, assessing a model's predictive accuracy is important. METHODS: We validated 3 colorectal cancer (CRC) microsimulation models against outcomes from the United Kingdom Flexible Sigmoidoscopy Screening (UKFSS) Trial, a randomized controlled trial that examined the effectiveness of one-time flexible sigmoidoscopy screening to reduce CRC mortality. The models incorporate different assumptions about the time from adenoma initiation to development of preclinical and symptomatic CRC. Analyses compare model predictions to study estimates across a range of outcomes to provide insight into the accuracy of model assumptions. RESULTS: All 3 models accurately predicted the relative reduction in CRC mortality 10 years after screening (predicted hazard ratios, with 95% percentile intervals: 0.56 [0.44, 0.71], 0.63 [0.51, 0.75], 0.68 [0.53, 0.83]; estimated with 95% confidence interval: 0.56 [0.45, 0.69]). Two models with longer average preclinical duration accurately predicted the relative reduction in 10-year CRC incidence. Two models with longer mean sojourn time accurately predicted the number of screen-detected cancers. All 3 models predicted too many proximal adenomas among patients referred to colonoscopy. CONCLUSION: Model accuracy can only be established through external validation. Analyses such as these are therefore essential for any decision model. Results supported the assumptions that the average time from adenoma initiation to development of preclinical cancer is long (up to 25 years), and mean sojourn time is close to 4 years, suggesting the window for early detection and intervention by screening is relatively long. Variation in dwell time remains uncertain and could have important clinical and policy implications.
BACKGROUND: Microsimulation models synthesize evidence about disease processes and interventions, providing a method for predicting long-term benefits and harms of prevention, screening, and treatment strategies. Because models often require assumptions about unobservable processes, assessing a model's predictive accuracy is important. METHODS: We validated 3 colorectal cancer (CRC) microsimulation models against outcomes from the United Kingdom Flexible Sigmoidoscopy Screening (UKFSS) Trial, a randomized controlled trial that examined the effectiveness of one-time flexible sigmoidoscopy screening to reduce CRC mortality. The models incorporate different assumptions about the time from adenoma initiation to development of preclinical and symptomatic CRC. Analyses compare model predictions to study estimates across a range of outcomes to provide insight into the accuracy of model assumptions. RESULTS: All 3 models accurately predicted the relative reduction in CRC mortality 10 years after screening (predicted hazard ratios, with 95% percentile intervals: 0.56 [0.44, 0.71], 0.63 [0.51, 0.75], 0.68 [0.53, 0.83]; estimated with 95% confidence interval: 0.56 [0.45, 0.69]). Two models with longer average preclinical duration accurately predicted the relative reduction in 10-year CRC incidence. Two models with longer mean sojourn time accurately predicted the number of screen-detected cancers. All 3 models predicted too many proximal adenomas among patients referred to colonoscopy. CONCLUSION: Model accuracy can only be established through external validation. Analyses such as these are therefore essential for any decision model. Results supported the assumptions that the average time from adenoma initiation to development of preclinical cancer is long (up to 25 years), and mean sojourn time is close to 4 years, suggesting the window for early detection and intervention by screening is relatively long. Variation in dwell time remains uncertain and could have important clinical and policy implications.
Authors: Marjolein van Ballegooijen; Carolyn M Rutter; Amy B Knudsen; Ann G Zauber; James E Savarino; Iris Lansdorp-Vogelaar; Rob Boer; Eric J Feuer; J Dik F Habbema; Karen M Kuntz Journal: Med Decis Making Date: 2011-06-14 Impact factor: 2.583
Authors: Reena V Chokshi; Christine E Hovis; Thomas Hollander; Dayna S Early; Jean S Wang Journal: Gastrointest Endosc Date: 2012-02-28 Impact factor: 9.427
Authors: Andrea N Burnett-Hartman; Polly A Newcomb; Amanda I Phipps; Michael N Passarelli; William M Grady; Melissa P Upton; Lee-Ching Zhu; John D Potter Journal: Am J Gastroenterol Date: 2012-06-12 Impact factor: 10.864
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz Journal: Ann Intern Med Date: 2008-10-06 Impact factor: 25.391
Authors: Chyke A Doubeni; Sheila Weinmann; Kenneth Adams; Aruna Kamineni; Diana S M Buist; Arlene S Ash; Carolyn M Rutter; V Paul Doria-Rose; Douglas A Corley; Robert T Greenlee; Jessica Chubak; Andrew Williams; Aimee R Kroll-Desrosiers; Eric Johnson; Joseph Webster; Kathryn Richert-Boe; Theodore R Levin; Robert H Fletcher; Noel S Weiss Journal: Ann Intern Med Date: 2013-03-05 Impact factor: 25.391
Authors: Frank van Hees; J Dik F Habbema; Reinier G Meester; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber Journal: Ann Intern Med Date: 2014-06-03 Impact factor: 25.391
Authors: David M Eddy; William Hollingworth; J Jaime Caro; Joel Tsevat; Kathryn M McDonald; John B Wong Journal: Med Decis Making Date: 2012 Sep-Oct Impact factor: 2.583
Authors: Ankur Pandya; Stephen Sy; Sylvia Cho; Sartaj Alam; Milton C Weinstein; Thomas A Gaziano Journal: Med Decis Making Date: 2017-05-10 Impact factor: 2.583
Authors: C L Gauvreau; N R Fitzgerald; S Memon; W M Flanagan; C Nadeau; K Asakawa; R Garner; A B Miller; W K Evans; C M Popadiuk; M Wolfson; A J Coldman Journal: Curr Oncol Date: 2017-12-20 Impact factor: 3.677
Authors: Maria DeYoreo; Iris Lansdorp-Vogelaar; Amy B Knudsen; Karen M Kuntz; Ann G Zauber; Carolyn M Rutter Journal: Med Decis Making Date: 2020-10-20 Impact factor: 2.583
Authors: Reinier G S Meester; Chyke A Doubeni; Ann G Zauber; Marjolein van Ballegooijen; Douglas A Corley; Iris Lansdorp-Vogelaar Journal: Int J Cancer Date: 2017-08-31 Impact factor: 7.396
Authors: Amy B Knudsen; Ann G Zauber; Carolyn M Rutter; Steffie K Naber; V Paul Doria-Rose; Chester Pabiniak; Colden Johanson; Sara E Fischer; Iris Lansdorp-Vogelaar; Karen M Kuntz Journal: JAMA Date: 2016-06-21 Impact factor: 56.272
Authors: Fernando Alarid-Escudero; Eline M Krijkamp; Petros Pechlivanoglou; Hawre Jalal; Szu-Yu Zoe Kao; Alan Yang; Eva A Enns Journal: Pharmacoeconomics Date: 2019-11 Impact factor: 4.981
Authors: Carolyn M Rutter; Jane J Kim; Reinier G S Meester; Brian L Sprague; Emily A Burger; Ann G Zauber; Mehmet Ali Ergun; Nicole G Campos; Chyke A Doubeni; Amy Trentham-Dietz; Stephen Sy; Oguzhan Alagoz; Natasha Stout; Iris Lansdorp-Vogelaar; Douglas A Corley; Anna N A Tosteson Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-17 Impact factor: 4.254
Authors: Maaike Buskermolen; Andrea Gini; Steffie K Naber; Esther Toes-Zoutendijk; Harry J de Koning; Iris Lansdorp-Vogelaar Journal: Med Decis Making Date: 2018-10-20 Impact factor: 2.583